

**NOTICE OF INTENTION TO DISCONTINUE DELATESTRYL CLASS ACTION –
TESTOSTERONE REPLACEMENT THERAPY FOR MALES WITH LOW TESTOSTERONE**

Please Read This Notice Carefully. It May Affect Your Legal Rights.

By Order of the Ontario Superior Court of Justice, all persons resident in Canada who have been prescribed and used Delatestryl are advised that:

In July 2014, Siskinds LLP commenced a proposed class proceeding in Ontario alleging that Delatestryl, a form of testosterone replacement therapy, intended to treat conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). The proposed class proceeding alleged that Delatestryl increased the risk of cardiovascular events and conditions. The various defendants in the action deny these allegations.

Siskinds is of the opinion that the proposed Delatestryl class proceeding is no longer viable. On this basis, Siskinds filed motion materials with the Ontario Superior Court of Justice to obtain approval of the discontinuance of the class proceeding. The discontinuance was approved by the Court and it will be filed and take effect on January 4, 2022.

The discontinuance relates to the proposed Delatestryl class action only. It does not relate to claims against various other manufacturers of testosterone replacement therapy products. If you do not know which brand of testosterone replacement therapy you were prescribed, you can retrieve your medical and pharmacy records, which will typically note the brand.

YOU SHOULD TAKE NOTICE THAT THE limitation period for bringing a claim, if there is any time left within it, could be impacted when the notice of discontinuance is filed with the Ontario Superior Court of Justice on January 4, 2022. On the expiry of a limitation period a right to sue may be extinguished.

TAKE NOTICE THAT because the limitation period for bringing a claim could be impacted by the filing of the notice of discontinuance, if you wish to pursue a court claim arising from Delatestryl in relation to cardiovascular events and conditions, you should take steps before January 4, 2022.

Siskinds will answer questions about the discontinuance or the running of the limitation period. Please contact Siskinds at:

SISKINDS LLP 680 Waterloo Street P.O. Box 2520 London, ON N6A 3V8 Jill McCartney Sharla Stroop (800) 461-6166 (226) 213-7353 jill.mccartney@siskinds.com sharla.stroop@siskinds.com	SISKINDS, DEMEULES sncrl Les Promenades du Vieux, Québec 43, rue Buade, bur 320 Québec, QC, G1R 4A2 Caroline Perrault (418) 694-2009 caroline.perrault@siskindsdesmeules.com
---	---

It is recommended that you obtain legal advice from Siskinds or a lawyer of your choice.

**PUBLICATION OF THIS NOTICE HAS BEEN AUTHORIZED BY THE ONTARIO SUPERIOR
COURT OF JUSTICE**